Reversible Cortical Blindness after Lung Transplantation

Mark T. Knower, Scott D. Pethke, Vincent G. Valentine

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Cyclosporine (CYA) is a calcineurin inhibitor widely used in immunosuppressive regimens after organ transplantation. Several neurologic side effects are frequently associated with CYA use; however, reversible cortical blindness is a rare manifestation of CYA toxicity traditionally seen after liver and bone marrow transplantation. This report presents a case of reversible cortical blindness after lung transplantation, then details the risk factors and clinical course of 28 previously well-documented cases of CYA-induced cortical blindness after transplantation. Identification of known risk factors, clinical clues, and typical radiographic findings may aid in the diagnosis of CYA-induced cortical blindness, since reduction in CYA dose or cessation of CYA therapy usually permits resolution of the neurologic effects.

Original languageEnglish (US)
Pages (from-to)606-612
Number of pages7
JournalSouthern Medical Journal
Volume96
Issue number6
DOIs
StatePublished - Jun 2003
Externally publishedYes

Fingerprint

Cortical Blindness
Lung Transplantation
Nervous System
Organ Transplantation
Immunosuppressive Agents
Bone Marrow Transplantation
Cyclosporine
Transplantation
Liver

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Reversible Cortical Blindness after Lung Transplantation. / Knower, Mark T.; Pethke, Scott D.; Valentine, Vincent G.

In: Southern Medical Journal, Vol. 96, No. 6, 06.2003, p. 606-612.

Research output: Contribution to journalArticle

Knower, Mark T. ; Pethke, Scott D. ; Valentine, Vincent G. / Reversible Cortical Blindness after Lung Transplantation. In: Southern Medical Journal. 2003 ; Vol. 96, No. 6. pp. 606-612.
@article{dea7e6e3ed8a40948c1e07af1e7ec66e,
title = "Reversible Cortical Blindness after Lung Transplantation",
abstract = "Cyclosporine (CYA) is a calcineurin inhibitor widely used in immunosuppressive regimens after organ transplantation. Several neurologic side effects are frequently associated with CYA use; however, reversible cortical blindness is a rare manifestation of CYA toxicity traditionally seen after liver and bone marrow transplantation. This report presents a case of reversible cortical blindness after lung transplantation, then details the risk factors and clinical course of 28 previously well-documented cases of CYA-induced cortical blindness after transplantation. Identification of known risk factors, clinical clues, and typical radiographic findings may aid in the diagnosis of CYA-induced cortical blindness, since reduction in CYA dose or cessation of CYA therapy usually permits resolution of the neurologic effects.",
author = "Knower, {Mark T.} and Pethke, {Scott D.} and Valentine, {Vincent G.}",
year = "2003",
month = "6",
doi = "10.1097/01.SMJ.0000054737.89938.F0",
language = "English (US)",
volume = "96",
pages = "606--612",
journal = "Southern Medical Journal",
issn = "0038-4348",
publisher = "Lippincott Williams and Wilkins",
number = "6",

}

TY - JOUR

T1 - Reversible Cortical Blindness after Lung Transplantation

AU - Knower, Mark T.

AU - Pethke, Scott D.

AU - Valentine, Vincent G.

PY - 2003/6

Y1 - 2003/6

N2 - Cyclosporine (CYA) is a calcineurin inhibitor widely used in immunosuppressive regimens after organ transplantation. Several neurologic side effects are frequently associated with CYA use; however, reversible cortical blindness is a rare manifestation of CYA toxicity traditionally seen after liver and bone marrow transplantation. This report presents a case of reversible cortical blindness after lung transplantation, then details the risk factors and clinical course of 28 previously well-documented cases of CYA-induced cortical blindness after transplantation. Identification of known risk factors, clinical clues, and typical radiographic findings may aid in the diagnosis of CYA-induced cortical blindness, since reduction in CYA dose or cessation of CYA therapy usually permits resolution of the neurologic effects.

AB - Cyclosporine (CYA) is a calcineurin inhibitor widely used in immunosuppressive regimens after organ transplantation. Several neurologic side effects are frequently associated with CYA use; however, reversible cortical blindness is a rare manifestation of CYA toxicity traditionally seen after liver and bone marrow transplantation. This report presents a case of reversible cortical blindness after lung transplantation, then details the risk factors and clinical course of 28 previously well-documented cases of CYA-induced cortical blindness after transplantation. Identification of known risk factors, clinical clues, and typical radiographic findings may aid in the diagnosis of CYA-induced cortical blindness, since reduction in CYA dose or cessation of CYA therapy usually permits resolution of the neurologic effects.

UR - http://www.scopus.com/inward/record.url?scp=0041382608&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0041382608&partnerID=8YFLogxK

U2 - 10.1097/01.SMJ.0000054737.89938.F0

DO - 10.1097/01.SMJ.0000054737.89938.F0

M3 - Article

C2 - 12938791

AN - SCOPUS:0041382608

VL - 96

SP - 606

EP - 612

JO - Southern Medical Journal

JF - Southern Medical Journal

SN - 0038-4348

IS - 6

ER -